Clarivate Epidemiology's coverage of non-alcoholic steatohepatitis (NASH) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the…
Cystic fibrosis (CF) is a genetic disease caused by any one of the more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR mutations lead…
To determine the trade-offs across key biosimilar attributes that surveyed medical oncologists are willing to make when considering which biosimilar to prescribe, we included an adaptive choice-…
Essential thrombocythemia (ET) is a hematological malignancy characterized by thrombocytosis. Patients are classified into different categories and, as such, receive different therapies and…
In June 2021, Biogen / Eisai’s anti-Aβ MAb aducanumab (Aduhelm) received accelerated approval from the FDA for the treatment of Alzheimer’s Disease (AD), rendering it the first potential DMT…
Approved therapies for Alzheimer's disease (AD) comprise symptomatic agents (e.g., donepezil, memantine) that provide only modest cognitive benefit for a limited period of time. A rapidly…
Clarivate Epidemiology’s coverage of hepatocellular carcinoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…
Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by varying degrees of hair loss due to the targeting of anagen hair follicles by the host immune system. The primary…
Clarivate Epidemiology’s coverage of PV comprises epidemiological estimates of key patient populations in the major emerging pharmaceutical markets (Brazil, China, India, Mexico, Russia, South…
As the number of gene therapy approvals rises, novel approaches to value assessment and reimbursement schemes for these innovative, high-cost treatments are rapidly gaining importance. Developers…
MARKET OUTLOOK For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure…
This content examines the market access factors that influence the success or failure of therapies for renal anemia. It is based on primary research with U.S. nephrologists and MCO pharmacy and…
Myelofibrosis (MF) is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Two high-priced JAK inhibitors (Incyte’s Jakafi and BMS’s Inrebic)…
Systemic sclerosis (SSc) is a rare, progressive, debilitating autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that manifests as Raynaud’s disease, skin…
Clarivate Epidemiology's coverage of venous thromboembolism (VTE) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed incidence of…